Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib + Pembrolizumab in KIT-mutant Melanoma
NCT04546074Phase 2Unknown
- Sponsor
- Keio University
- Start
- Sep 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in melanoma, sponsored by Keio University. Primary endpoint: Objective Response Rate at 6 weeks. Status: unknown.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04546074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546074.